Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
This article was originally published in The Tan Sheet
Executive Summary
Emerging markets, the key driver for Reckitt Benckiser's nearly 20% net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S.
You may also be interested in...
Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition
Reckitt Benckiser reports net revenue up 15% in its latest earnings period on strong sales of OTC products and new business from the now fully integrated SSL International brands.
Reckitt Likely To Shed SSL Brands As Profits Trickle In
Reckitt Benckiser's acquisition of SSL has yet to produce sizeable returns for the company, leading the firm to consider spinning off some acquired brands, company officials said.
Reckitt Continues Asian Push With $724M Paras Purchase
Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.